LP
PTGX icon

LMR Partners’s Protagonist Therapeutics PTGX Stock Holding History

LMR Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.66M Buy
38,000
+7,150
+23% +$747K 0.02% 679
2026
Q1 		$3.25M Sell
30,850
-9,150
-23% -$810K 0.01% 756
2025
Q4 		$3.49M Buy
+40,000
New +$3.27M 0.01% 673
2018
Q3 		– Sell
-31,228
Closed -$210K – 470
2018
Q2 		$210K Buy
+31,228
New +$240K 0.01% 409

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

LMR Partners's PTGX Position: Q2 2026 in Review

LMR Partners increased its Protagonist Therapeutics (PTGX) stake by 23% in Q2 2026, buying an estimated $747K and bringing the position to 38,000 shares worth $4.66M. The position accounts for 0.02% of the portfolio, ranked #679.

LMR Partners first reported a position in PTGX in Q2 2018 and has held it in 4 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • LMR Partners held 38,000 shares of Protagonist Therapeutics worth $4.66M as of Q2 2026.
  • LMR Partners bought 7,150 Protagonist Therapeutics shares in Q2 2026, an estimated $747K.
  • Protagonist Therapeutics made up 0.02% of LMR Partners's portfolio in Q2 2026, its #679 holding.
  • LMR Partners first reported a position in Protagonist Therapeutics in Q2 2018 and has held it in 4 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.